Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05082415 · ClinicalTrials.gov registry record
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 9,456
- Enrollment target
NCT05082415 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 9,456 participants.
The verdict
NCT05082415 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 9,456 participants
- Enrollment target
Study Summary
This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab. Evidence was generated to describe their patient characteristics and clinical outcomes. The study was conducted using the IRIS Registry.
Interventions
- DRUG Brolucizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,456 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2020-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05082415
The ClinicalTrials.gov registry entry for NCT05082415 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9,456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brolucizumab is the first listed.
NCT05082415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05082415 about?
NCT05082415 is a clinical study titled "Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)". This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab. Evidence was generated to describe their patient characteristics and clinical outcomes. The study was conducted using the IRIS Registry.
What is the current status of trial NCT05082415?
This trial is currently completed. The enrollment target is 9,456 participants. The study started on 2020-06-03. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT05082415?
The interventions under investigation include: Brolucizumab (DRUG).
Who is sponsoring clinical trial NCT05082415?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.